A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Mar 2023 Planned number of patients changed from 100 to 427.
- 30 Dec 2021 Status changed from not yet recruiting to recruiting.
- 22 Jun 2021 New trial record